Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Novacea, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing novel cancer therapies. Novacea has three product candidates in clinical trials, including Asentar, which currently is in a Phase 3 clinical trial for androgen-independent prostate cancer, or AIPC. Novacea’s second product candidate, oral vinorelbine, is expected to enter a registration trial for metastatic breast cancer in the second half of 2006. Novacea’s third product candidate, AQ4N, is expected to advance into a Phase 1/2 clinical trial in the second half of 2006 for glioblastoma multiforme in combination with radiation and chemotherapy. ( www.novacea.com )
Novacea Inc.
601 Gateway Blvd. Suite 800
South San Francisco, California 94080
USA
Tel: (650) 228-1800
Fax: (650) 228-1088